Johnson & Johnson JNJ

$268.73 +2.43 (0.91%)

Valuation

Market cap
641,066,624,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
24.77
Forward PE
23.73
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
5,774,800
Avg volume
6,984,938
Day's range
$264.83 – $269.09
Shares out
2,407,310,000
Stochastic %K
83%
Beta
0.21
Analysts
Strong Sell
Price target
$282.24

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

haha1978 Oct 28, 2:08 AM
$CPIX $XBI $JNJ $SLS Soon a p3 will start. It will be nice to beable stop cancer metasis of solid tumors. In the mean time FDA granted AA greenlight with a p2 only for DMD Cardiomyopathy.
0 replies
SuperGreenToday Oct 28, 1:55 AM
$JNJ Share Price: $268.78 Contract Selected: Nov 20, 2026 $270 Calls Buy Zone: $5.18 – $6.41 Target Zone: $9.41 – $11.50 Potential Upside: 71% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/
0 replies
thatsolardude365 Oct 27, 9:33 PM
$JNJ: trial results are split in the talc litigation. In early June 2026 a jury sided with J&J in a case brought by three women, even as MDL 2738 keeps litigating in New Jersey. No settlement, nothing to claim. Open Class Actions.
0 replies
UncleSteven Oct 27, 8:59 PM
$SMH $AIQ $DRAM All these AI double beats and people want $JNJ
0 replies
SparkyReturns Oct 27, 6:48 PM
$ICU Cures sepsis and AKI. 11 Million Market Cap. Uh huh. Sure. Not for long. https://finance.yahoo.com/healthcare/articles/icu-quelimmune-demonstrates-statistically-significant-111100428.html $JNJ $RFMS.X $BAX $BDX
2 replies
chursinow62 Oct 27, 6:33 PM
$JNJ Big boys loading
0 replies
chursinow62 Oct 27, 6:31 PM
$JNJ big houses loading this name now
0 replies
SellasgpsCurativeBAT11 Oct 27, 6:11 PM
$ABBV $BMY $JNJ $PFE $SLS PPS will start moving Rapidly towards the base floor before the PR hits. Good Bye 👋🏿 Repositioners, Traders, Shorts 🔥 ✌️🙏❤️‍🩹
0 replies